Key result
Oral anticancer therapy is linked to potential QT-prolonging drug interactions in ~17% of advanced cancer patients.
Why the study?
Patients with cancer are at increased risk of QT interval prolongation due to polypharmacy and drug-drug interactions, while outpatient ECG monitoring appears underused in those receiving oral anticancer drugs. This study aimed to evaluate the prevalence and characteristics of potential QT interval-prolonging drug-drug interactions in patients receiving oral anticancer therapy.
Observational (n=1,732)
Answers are grounded in this paper and cite their sources.
Nearly 1 in 6 patients with advanced cancer receiving oral anticancer drugs experience potential QT-prolonging drug-drug interactions, underscoring the need for routine medication review and ECG monitoring in cardio-oncology.
Background Patients with cancer are at increased risk of QT interval prolongation because of polypharmacy and concomitant use of QT‐prolonging medications. Drug–drug interactions (DDIs) may further increase this risk. Outpatient electrocardiogram (ECG) monitoring appears to be underused among patients receiving oral anticancer drugs (OADs). Our study objective was to evaluate the prevalence and characteristics of potential QT interval–prolonging drug–drug interactions (QT pDDIs) in patients with cancer receiving OAD therapy. Methods A retrospective observational study was conducted using electronic health record data from 3697 patients with advanced cancer. Patients who received at least one OAD were included in the analysis. Potential QT‐related DDIs were identified through overlap prescriptions of concomitant medications associated with QT prolongation and/or Cytochrome P450‐ (CYP‐) or drug transporter‐mediated interactions during OAD exposure. Descriptive analyses were performed to characterize the prevalence and types of QT pDDIs. Results Of the 3697 patients, 1732 (46.8%) received at least one OAD and were included in the analysis. Of these, 17.1% experienced at least one QT pDDI. Among those patients, 47.5% experienced PD‐QT pDDIs only, 21.2% experienced PK‐QT pDDIs only, and 31.3% experienced both PD‐ and PK‐QT pDDIs during OAD exposure. Concurrent PD and PK mechanisms occurred simultaneously in 30.6% of patients with QT‐pDDIs. Approximately 48% of identified QT pDDIs involved at least one OAD, most commonly pazopanib (13.5%), palbociclib (11.3%), and vandetanib (8.4%). Conclusion QT pDDIs were common among patients with cancer receiving OADs, highlighting the importance of comprehensive DDI screening, careful medication review, and enhanced cardiac monitoring strategies in oncology practice.
No takes yet. Share an insight, caveat, or question.
Alhurayri et al. (2026) conducted an observational in Advanced cancer receiving oral anticancer drugs (OADs) (n=1,732). Oral anticancer drug (OAD) therapy with concomitant medications was evaluated on Prevalence of potential QT interval-prolonging drug-drug interactions (QT pDDIs). Oral anticancer drug therapy was associated with potential QT-prolonging drug-drug interactions in 17.1% of patients with advanced cancer, most commonly involving pazopanib.
Synapse has enriched 10 related papers. Consider them for comparative context: